Palvella Therapeutics (PVLA) EBIT Margin: 2014-2024
Historic EBIT Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to 2,412.15%.
- Palvella Therapeutics' EBIT Margin rose 138167.00% to 2,412.15% in Q4 2024 from the same period last year, while for Dec 2024 it was -1,482.12%, marking a year-over-year decrease of 145447.00%. This contributed to the annual value of 3,277.91% for FY2024, which is 330563.00% up from last year.
- According to the latest figures from Q4 2024, Palvella Therapeutics' EBIT Margin is 2,412.15%, which was up 4.83% from 2,300.91% recorded in Q3 2024.
- Palvella Therapeutics' 5-year EBIT Margin high stood at 2,412.15% for Q4 2024, and its period low was -3,318.87% during Q1 2024.
- Moreover, its 3-year median value for EBIT Margin was -66.70% (2022), whereas its average is 70.82%.
- The largest annual percentage gain for Palvella Therapeutics' EBIT Margin in the last 5 years was 236,140bps (2024), contrasted with its biggest fall of 254,718bps (2024).
- Palvella Therapeutics' EBIT Margin (Quarterly) stood at -661.21% in 2020, then skyrocketed by 53,094bps to -130.27% in 2021, then crashed by 6,677bps to -197.04% in 2022, then surged by 122,753bps to 1,030.48% in 2023, then skyrocketed by 138,167bps to 2,412.15% in 2024.
- Its EBIT Margin was 2,412.15% in Q4 2024, compared to 2,300.91% in Q3 2024 and -3,318.87% in Q1 2024.